N/A
N=601
CBTpro: Scaling up CBT for Psychosis Using Simulated Patients and Spoken Language Technologies
Psychosis · Schizophrenia · Schizo Affective Disorder · Bipolar Disorder · Depressive Disorder
Bottom Line
View on ClinicalTrials.gov: NCT05127837 ↗Enrolled (actual)
601
Serious AEs
0.0%
Results posted
Feb 2026
Primary outcome: Primary: Revised Green Paranoid Thoughts Scale (R-GPTS) Mean Score — 12.1; 12.3; 12.1; 11.4 Score on a Scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- CBTpro (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Washington
- Primary completion
- Dec 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Revised Green Paranoid Thoughts Scale (R-GPTS) Mean Score |
12.1; 12.3; 12.1; 11.4; 11.1; 11 | — |
| SECONDARY Change in CHOICE-SF (Choice of Outcome in CBT for Psychosis- Short Form) |
6.2; 6.1; 6.1; 6.4; 6.1; 6.6 | — |
| SECONDARY Change in in Sheehan Disability Scale (SDS) Mean Score |
14.5; 14.2; 14.0; 13.9; 14.4; 13.1 | — |
Summary
The primary objective of this grant is to develop and evaluate an Artificial Intelligence-based clinical training tool--CBTpro--to support high-quality skills training in CBT for psychosis (CBTp). CBTpro will provide a rapid means of scaling and sustaining high-quality CBTp in routine care settings across the US.
Eligibility Criteria
Client Inclusion: Adults who speak English, meet with their provider who is participating in the study at least bi-weekly (2x a month), and do not plan to leave services in the next 6 months. Qualifying diagnoses for clients include: schizophrenia; schizoaffective disorder; schizophreniform disorder; delusional disorder; other specified schizophrenia spectrum and other psychotic disorder; unspecified schizophrenia spectrum or other psychotic disorder; bipolar disorder with psychotic features; major depressive disorder with psychotic features
Exclusion criteria: Dx of psychosis secondary to substance intoxication
Data sourced from ClinicalTrials.gov (NCT05127837). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.